Collaboration and License Agreements (Tables)

9 Months Ended

Sep. 30, 2020

Collaboration And License Agreements [Abstract]

Schedule of Revenue from Collaboration Agreements

Revenue from collaboration agreements for the three and nine months ended September 30, 2020 and 2019 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):

	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
	2020		2019		2020		2019
Restated Roche Agreement	$	1,395		1,762	$	7,424	$	3,875
Biogen License Agreement		3,525		642		6,827		1,707
Calico License Agreement		3,527		2,960		10,682		7,590
	$	8,447	$	5,364	$	24,933	$	13,172

Schedule of Financial Information Related to Collaboration and License Agreements

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2020 and December 31, 2019 (in thousands):

	AS OF SEPTEMBER 30, 2020
	(unaudited)
DESCRIPTION	ACCOUNTS RECEIVABLE		DEFERRED REVENUE, CURRENT		DEFERRED REVENUE, NET OF CURRENT		DEFERRED REVENUE, TOTAL
Restated Roche Agreement	$	583	$	7,821	$	31,286	$	39,107
Biogen License Agreement		631		13,694		28,597		42,291
Calico License Agreement		2,927		2,400		1,200		3,600
	$	4,141	$	23,915	$	61,083	$	84,998

	AS OF DECEMBER 31, 2019
DESCRIPTION	ACCOUNTS RECEIVABLE		DEFERRED REVENUE, CURRENT		DEFERRED REVENUE, NET OF CURRENT		DEFERRED REVENUE, TOTAL
Restated Roche Agreement	$	—	$	12,164	$	32,784	$	44,948
Biogen License Agreement		275		6,141		36,934		43,075
Calico License Agreement		4,348		2,400		3,000		5,400
	$	4,623	$	20,705	$	72,718	$	93,423